GHB formulation and method for its manufacture
The present application relates to GHB formulations and methods for manufacturing the same.
1. A method of treating narcolepsy, cataplexy, or excessive daytime sleepiness in a patient in need thereof, the method comprising:
administering a single daily dose of gamma-hydroxybutyrate to the patient with food or a caloric liquid, the single daily dose comprising controlled release gamma-hydroxybutyrate-containing particles and immediate release gamma-hydroxybutyrate-containing particles, wherein the single daily dose comprises an amount of gamma-hydroxybutyrate equivalent to from 4.0 g to 12.0 g of sodium gamma-hydroxybutyrate; and wherein the immediate release and controlled release gamma-hydroxybutyrate-containing particles in the single daily dose together provide therapeutically effective levels of gamma-hydroxybutyrate for about 6-8 hours after administration of the single daily dose to the patient.
2. The method of claim 1 , wherein the single daily dose comprises an amount of gamma-hydroxybutyrate equivalent to about 4.0 g, about 6 g, about 7.5 g or about 9 g of sodium gamma-hydroxybutyrate.
3. The method of claim 1 , wherein the single daily dose is in a unit dose.
4. The method of claim 3 , wherein the unit dose is a sachet.
5. The method of claim 1 , wherein the single daily dose is administered with food.
6. The method of claim 3 , wherein the unit dose contains an amount of gamma-hydroxybutyrate equivalent to about 6 g of sodium gamma-hydroxybutyrate.
7. The method of claim 3 , wherein the unit dose contains an amount of gamma-hydroxybutyrate equivalent to about 7.5 g of sodium gamma-hydroxybutyrate.
8. The method of claim 3 , wherein the unit dose contains an amount of gamma-hydroxybutyrate equivalent to about 9 g of sodium gamma-hydroxybutyrate.
9. A method of treating narcolepsy, cataplexy, or excessive daytime sleepiness in a patient in need thereof, the method comprising:
administering to the patient controlled release gamma-hydroxybutyrate-containing particles and immediate release gamma-hydroxybutyrate-containing particles once per day, and
wherein the once per day administration provides therapeutically effective levels of gamma-hydroxybutyrate for about 6-8 hours after administration to the patient, and wherein the controlled release particles and immediate release particles are administered with food or a caloric liquid.
10. The method of claim 9 , wherein the controlled release and immediate release particles comprise gamma-hydroxybutyrate equivalent to from about 4.0 g to about 12.0 g of sodium gamma-hydroxybutyrate.
11. The method of claim 9 , wherein the controlled release and immediate release particles comprise gamma-hydroxybutyrate equivalent to about 4.0 g, about 6 g, about 7.5 g or about 9 g of sodium gamma-hydroxybutyrate.
12. The method of claim 9 , wherein the controlled release and immediate release particles comprise gamma-hydroxybutyrate equivalent to about 6 g of sodium gamma-hydroxybutyrate.
13. The method of claim 9 , wherein the controlled release and immediate release particles comprise gamma-hydroxybutyrate equivalent to about 7.5 g of sodium gamma-hydroxybutyrate.
14. The method of claim 9 , wherein the controlled release and immediate release particles comprise gamma-hydroxybutyrate equivalent to about 9 g of sodium gamma-hydroxybutyrate.
15. The method of claim 9 , wherein the controlled release and immediate release particles are administered with food.